

11-03-2000

rce
e

101504698

RECORDATION FORM COVER SHEET
PATENTS ONLY

19-17-08

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

☒ New

☐ Resubmission (Non-Recordation)
Document ID#

☐ Correction of PTO Error
Reel # Frame #

☐ Corrective Document
Reel # Frame #

Conveyance Type

☒ Assignment ☐ Security Agreement

☐ License ☐ Change of Name

☐ Merger ☐ Other

U.S. Government
(For Use ONLY by U.S. Government Agencies)

☐ Departmental File ☐ Secret File

Conveying Party(ies)

☐ Mark if additional names of conveying parties attachedName (line 1) Execution Date
Month Day Year
Name (line 2)

Second Party

Name (line 1) Execution Date
Month Day Year
Name (line 2)

Receiving Party

☐ Mark if additional names of receiving parties attachedName (line 1) ☐ If document to be recorded
is an assignment and the
receiving party is not
domiciled in the United
States, an appointment
of a domestic
representative is attached.
(Designation must be a
separate document from
Assignment.)Name (line 2) Address (line 1) Address (line 2) Address (line 3)

NJ

07727

City

State/Country

Zip Code

Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name Address (line 1) Address (line 2) Address (line 3) Address (line 4)

FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

PATENT

REEL: 011195 FRAME: 0273

Correspondent Name and Address

Area Code and Telephone Number 908-654-5000

Name LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

Address (line 1) 600 South Avenue West

Address (line 2) Westfield NJ 07090

Address (line 3)

Address (line 4)

Pages

Enter the total number of pages of the attached conveyance document including any attachments.

2

Application Number(s) or Patent Number(s)

☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)

Patent Number(s)

5154697

If this document is being filed together with a new Patent Application, enter the date the patent application was signed by the first named executing inventor.

Month Day Year

Patent Cooperation Treaty (PCT)

Enter PCT application number
only if a U.S. Application Number
has not been assigned.

PCT

PCT

PCT

PCT

PCT

PCT

Number of Properties

Enter the total number of properties involved.

1

Fee Amount

Fee Amount for Properties Listed (37 CFR 3.41): \$ 40.00

Method of Payment:
Deposit AccountEnclosed ☐Deposit Account ☒

(Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number:

12-1095

Authorization to charge additional fees:

Yes ☒No ☐

Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

STEPHEN B. GOLDMAN

Name of Person Signing

Signature

Date

10/12/00

Sale of Ownership Rights to Supra Sacral Device

Supra Medical Corp. here after referred to as Supra, agrees to sell all rights of ownership to its Supra Sacral device to Wound Care Systems and / or Wound Healing Systems, hereafter referred to as Wound. The following outlines the responsibilities of both parties:

1. **Product:** Supra Sacral device, a flexible, plastic cushion-like device for dispensing topical oxygen to skin sores and ulcers as demonstrated in the attached article from the September / October 1992 issue of Journal of Wound Care.
2. **Ownership Rights:** Supra conveys to Wound all rights of ownership to the Supra Sacral device to Wound that would be required by Wound to manufacture and distribute the device. These rights would include items such as patents, FDA 510(K) clearance, manufacturing dies, plastic and adhesive materials, etc. There is no inventory of Sacral devices.
3. **Representation:** Supra conveys its ownership rights to Wound on an "as is" basis and makes no representation as to their worth, timeliness, or accuracy. Supra conveys to Wound the Sacral patent without any reassurance as to its exclusivity and competitive protection.
4. **Exclusion:** Supra recognizes that its Supra Oxyhealer[®] may be covered by the same 510(K) clearance accorded the Supra Sacral device. Therefore in transferring rights to this clearance to Wound, Supra retains the right to coverage of its Oxyhealer[®] under the Sacral 510(K) and Wound agrees.


Supra recognizes the remote possibility that its recently developed Supra Oxyhealer[®], which is not being conveyed under this sales agreement, may be covered by the Supra Sacral patent 5,154,697. Accordingly, Wound grants Supra a cost free right for the life of the Supra Sacral patent to unlimited coverage for the exclusive development and commercialization of the Supra Oxyhealer[®].


5. **Confidentiality:** Wound recognizes that Supra has sponsored clinical studies that involved the Sacral device. These studies were covered by agreements requiring confidentiality with respect to the progress and the end results. Supra pledged to obtain written permission from these institutions before making revelations to the marketplace. Wound agrees to be bound by

these agreements.

6. **Price:** Wound agrees to pay Supra \$110,000 for the ownership rights according to the following terms:
- a) \$25,000 will be paid upon the signing of this agreement.
 - b) \$5,000 will be paid on May 1, 1993 and on the first business day of the next four months succeeding, to total \$25,000.
 - c) \$2 will be paid as a royalty on the first 30,000 Sacral units to be manufactured to Wound, to total \$60,000.
7. Any present or future liabilities for clinical studies regarding topical oxygen and the sacral device will be shared equally between Supra and Wound.
8. There will be no representation, oral or written that Supra is associated with Wound, its affiliates or subsidiaries.
9. The name Supra or Topox will not be used on any of the products sold by Wound

Agreed to on this 26 day of April, 1993

 Chairman
Supra Medical Corp. (Title)

 (Title)
Wound Care Systems, Wound Healing Systems